active: true
address:
    address1: 50 NORTHERN AVENUE
    city: BOSTON
    postal_code: '02210'
    state: MA
branding:
    icon_url: https://api.polygon.io/v1/reference/company-branding/dnJ0eC5jb20/images/2025-04-04_icon.jpeg
    logo_url: https://api.polygon.io/v1/reference/company-branding/dnJ0eC5jb20/images/2025-04-04_logo.svg
cik: 0000875320
composite_figi: BBG000C1S2X2
currency_name: usd
description: Vertex Pharmaceuticals is a global biotechnology company that discovers
    and develops small-molecule drugs for the treatment of serious diseases. Its key
    drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic
    fibrosis, where Vertex therapies remain the standard of care globally. Vertex
    has diversified its portfolio through Casgevy, a gene-editing therapy for beta
    thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication
    approved for the treatment of moderate-to-severe acute pain in adults. Additionally,
    Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases.
    Vertex is also investigating cell therapies to deliver a potential functional
    cure for type 1 diabetes.
homepage_url: https://www.vrtx.com
list_date: '1991-07-31'
locale: us
market: stocks
market_cap: 99420602738.26999
name: Vertex Pharmaceuticals Inc
phone_number: (617) 341-6393
primary_exchange: XNAS
round_lot: 100
share_class_figi: BBG001S68LJ8
share_class_shares_outstanding: 256390651
sic_code: '2834'
sic_description: PHARMACEUTICAL PREPARATIONS
ticker: VRTX
ticker_root: VRTX
total_employees: 6100
type: CS
weighted_shares_outstanding: 256390651
